Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Y. Qiu (Princeton, United States of America), J. Zhu (Princeton, United States of America), B. Elpers (Princeton, United States of America), J. Jiang (Princeton, United States of America), A. Ogbomo (Plano, United States of America), R. Mallampati (Plano, United States of America), C. Byrne (Plano, United States of America), J. Tang (Plano, United States of America), A. Fischer (Princeton, United States of America)
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Session: Interstitial lung disease around the world
Session type: E-poster
Number: 3762
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Qiu (Princeton, United States of America), J. Zhu (Princeton, United States of America), B. Elpers (Princeton, United States of America), J. Jiang (Princeton, United States of America), A. Ogbomo (Plano, United States of America), R. Mallampati (Plano, United States of America), C. Byrne (Plano, United States of America), J. Tang (Plano, United States of America), A. Fischer (Princeton, United States of America). Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis. 3762
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: